The Genetics and Prenatal Diagnosis Center, The Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
The Department of Central Laboratory, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471003, Henan, China.
BMC Med Genomics. 2021 Mar 29;14(1):92. doi: 10.1186/s12920-021-00935-w.
Hereditary retinopathy is a significant cause of blindness worldwide. Despite the discovery of many mutations in various retinopathies, a large number of patients remain genetically undiagnosed. Targeted next-generation sequencing of the human genome is a suitable approach for the molecular diagnosis of retinopathy.
We describe a cohort of 211 families from central China with various forms of retinopathy; 95 patients were investigated using multigene panel sequencing, and the other 116 with suspected Leber hereditary optic neuropathy (LHON) were tested by Sanger sequencing. The detected variation of targeted sequencing was verified by PCR-based Sanger sequencing. We performed a comprehensive analysis of the cases using sequencing data and ophthalmologic examination information.
Potential causal mutations were identified in the majority of families with retinopathy (57.9% of 95 families) and suspected LHON (21.6% of 116 families). There were 68 variants of a certain significance distributed in 31 known disease-causing genes in the 95 families; 37 of the variants are novel and have not been reported to be related to hereditary retinopathy. The NGS panel solution provided a 45.3% potential diagnostic rate for retinopathy families, with candidate gene mutations of undefined pathogenicity revealed in another 12.6%of the families.
Our study uncovered novel mutations and phenotypic aspects of retinopathy and demonstrated the genetic and clinical heterogeneity of related conditions. The findings show the detection rate of pathogenic variants in patients with hereditary retinopathy in central China as well as the diversity and gene distribution of these variants. The significance of molecular genetic testing for patients with hereditary retinopathy is also highlighted.
遗传性视网膜病变是全球范围内导致失明的一个重要原因。尽管已经发现了多种不同视网膜病变中的许多突变,但仍有大量患者的遗传诊断未得到明确。针对人类基因组的靶向下一代测序是一种适用于视网膜病变分子诊断的方法。
我们描述了一个来自中国中部的 211 个具有各种形式视网膜病变的家族的队列;对 95 名患者进行了多基因panel 测序研究,对另外 116 名疑似 Leber 遗传性视神经病变(LHON)患者进行了 Sanger 测序。通过基于 PCR 的 Sanger 测序验证了靶向测序检测到的变异。我们使用测序数据和眼科检查信息对这些病例进行了全面分析。
在大多数具有视网膜病变的家族(95 个家族中的 57.9%)和疑似 LHON 的家族(116 个家族中的 21.6%)中,都鉴定出了潜在的致病突变。在 95 个家族中,有 31 个已知致病基因中分布着 68 个具有一定意义的变异,其中 37 个是新的,尚未报道与遗传性视网膜病变有关。NGS panel 解决方案为视网膜病变家族提供了 45.3%的潜在诊断率,在另外 12.6%的家族中揭示了候选基因突变的致病性不明。
我们的研究揭示了视网膜病变的新突变和表型特征,并证明了相关疾病的遗传和临床异质性。这些发现表明了在中国中部遗传性视网膜病变患者中致病变异的检出率以及这些变异的多样性和基因分布。还强调了对遗传性视网膜病变患者进行分子遗传检测的重要性。